Caroline Hroncich

home / authors / caroline-hroncich-1

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

Articles

Public Health Organizations Pen Letter to House and Senate Committees

Caroline Hroncich

August 17th 2016

Nine public health organizations submitted a letter to US House and Senate committees citing concerns about Section 11 of the FDA and NIH Workforce Authorities Modernization Act.

Keytruda Proves Superior to Chemotherapy in Phase III Trials

Caroline Hroncich

June 16th 2016

Keytruda was shown to be superior to chemotherapy in the treatment of patients with non-small cell lung cancer.

Study: Patients Who Have Reactive Responses to Infliximab Should Not Switch to Biosimilar Versions

Caroline Hroncich

June 15th 2016

A study published in BMJ indicates that rheumatic patients with anti-infliximab antibodies may have a similar cross reaction to infliximab biosimilars.

FDA Reiterates Decision to Require Suffixes in Biosimilar Naming

Caroline Hroncich

June 6th 2016

The agency reiterated its earlier decision to require suffixes in biosimilar naming, but was unclear on suffix meaning.

FDA Approves Atezolizumab

Caroline Hroncich

May 19th 2016

Genentech received accelerated approval for its immunotherapy atezolizumab for the treatment of bladder cancer.